Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy Albrecht Bufe, PhD, MD, Peter Eberle, MD, Eivy.

Slides:

Advertisements

Similar presentations

Joint modeling of parentally reported and physician-confirmed wheeze identifies children with persistent troublesome wheezing Danielle C.M. Belgrave, MSc,

Advertisements

Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy Ravi S. Swamy, MD, Neha Reshamwala,

Does BCG vaccination protect against childhood asthma

Trichuris suis ova therapy for allergic rhinitis: A randomized, double-blind, placebo- controlled clinical trial Peter Bager, PhD, John Arnved, MD, Steen.

Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses Giuseppina Rotiroti, MD, Mohamed Shamji, PhD, Stephen.

Efficacy and safety of birch pollen immunotherapy for local allergic rhinitis Andrzej Bożek, MD, PhD, Krzysztof Kołodziejczyk, MD, PhD, Jerzy Jarząb,

Allergen immunotherapy: A practice parameter third update

Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses Stephen R. Durham,

SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial Stephen.

High-titer IgE antibody specific for pollen allergens in northern California is associated with both wheezing and total serum IgE Elizabeth A. Erwin,

Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses Stephen R. Durham,

Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5– grass pollen tablet for seasonal allergic rhinitis Alain Didier, MD,

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults Peter S. Creticos, MD, Jennifer Maloney,

Epicutaneous allergen-specific immunotherapy ameliorates grass pollen–induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation.

Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: A meta-analysis–based comparison Danilo Di.

Is 9 more than 2 also in allergic airway inflammation?

Preventive effect of nasal filters on allergic rhinitis: A randomized, double-blind, placebo- controlled crossover park study Peter Kenney, BSc, Ole Hilberg,

SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial Stephen.

Joe K. Gerald, MD, PhD, Roni Grad, MD, William C. Bailey, MD, Lynn B

Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies Louisa K. James, PhD, Mohamed H. Shamji,

Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber Friedrich Horak, MD, Petra.

Intralymphatic immunotherapy with 2 concomitant allergens, birch and grass: A randomized, double-blind, placebo-controlled trial Laila Hellkvist, MD,

BCG vaccination and allergy: A systematic review and meta-analysis

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

Allergy testing in predicting outcome of open food challenge to peanut

Reply Journal of Allergy and Clinical Immunology

Peter M. Wolfgram, MD, David B. Allen, MD

Does BCG vaccination protect against childhood asthma

The SQ tree SLIT-tablet is highly effective and well tolerated: Results from a randomized, double-blind, placebo-controlled phase III trial Tilo Biedermann,

A. Wesley Burks, MD, Robert A. Wood, MD, Stacie M. Jones, MD, Scott H

Debra J. Palmer, PhD, Thomas R. Sullivan, BMa&CompSc(Hons), Michael S

Phillip Lieberman, MD, Michael Tankersley, MD

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

Trichuris suis ova therapy for allergic rhinitis: A randomized, double-blind, placebo- controlled clinical trial Peter Bager, PhD, John Arnved, MD, Steen.

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Sublingual allergen immunotherapy with a liquid birch pollen product in patients with seasonal allergic rhinoconjunctivitis with or without asthma Oliver.

Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial Hendrik.

Allergen-specific immunotherapy with recombinant grass pollen allergens Marek Jutel, MD, Lothar Jaeger, MD, Roland Suck, PhD, Hanns Meyer, Dipl Math,

A cluster-randomized trial shows telephone peer coaching for parents reduces children's asthma morbidity Jane M. Garbutt, MB, ChB, Yan Yan, MD, PhD,

Claus Bachert, MD, PhD, Cezmi A. Akdis, MD

What is an “eosinophilic phenotype” of asthma?

Sublingual immunotherapy with once-daily grass allergen tablets: A randomized controlled trial in seasonal allergic rhinoconjunctivitis Stephen R. Durham,

Evaluation of Allergen Immunotherapy

Autophagy: Nobel Prize 2016 and allergy and asthma research

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

House dust mite sublingual immunotherapy: Results of a US trial

Geographic variability in childhood asthma prevalence in Chicago

Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy? Marianne Witten, MD, PhD, Hans-Jørgen Malling, MD, Lars.

Mary F. Linehan, PhD, Timothy L. Frank, MD, Michelle L

Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis Karl-Christian Bergmann, MD, Pascal Demoly,

Local allergic rhinitis: Allergen tolerance and immunologic changes after preseasonal immunotherapy with grass pollen Carmen Rondón, MD, PhD, Natalia.

Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years Ronald Dahl, MD,

Long-term clinical efficacy in grass pollen–induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet Stephen.

Epinephrine (adrenaline) absorption from new-generation, taste-masked sublingual tablets: A preclinical study Ousama Rachid, BPharm, MSc, Mutasem M.

Reply Journal of Allergy and Clinical Immunology

Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen–induced rhinoconjunctivitis

Efficacy and safety of sublingual tablets of house dust mite allergen extracts: Results of a dose-ranging study in an environmental exposure chamber

Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite–induced allergic.

Thunderstorm-related asthma attacks

Early improvement in basophil sensitivity predicts symptom relief with grass pollen immunotherapy Johannes Martin Schmid, MD, Peter Adler Würtzen, PhD,

Macrolide antibiotics and asthma treatment

Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses Giuseppina Rotiroti, MD, Mohamed Shamji, PhD, Stephen.

Placental transfer of allergen-specific IgG but not IgE from a specific immunotherapy– treated mother Sabine Flicker, PhD, Katharina Marth, MD, Heinz.

Effect of grass sublingual tablet immunotherapy is similar in children and adults: A Bayesian approach to design pediatric sublingual immunotherapy trials

Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen Piyush Patel, MD, Tom Holdich, MBBS,

Safety and efficacy of repeated monthly carboplatin desensitization

Allergen-specific IgG antibody levels modify the relationship between allergen-specific IgE and wheezing in childhood Adnan Custovic, MD, PhD, Lars Soderstrom,

Natural history of cow’s milk allergy

Primary prevention of asthma and allergy

Presentation transcript:

Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy Albrecht Bufe, PhD, MD, Peter Eberle, MD, Eivy Franke-Beckmann, MD, Jürgen Funck, MD, Martin Kimmig, MD, Ludger Klimek, MD, Roland Knecht, MD, Volker Stephan, MD, Bente Tholstrup, MSc, Christian Weißhaar, MD, Friedrich Kaiser, MD Journal of Allergy and Clinical Immunology Volume 123, Issue 1, Pages 167-173.e7 (January 2009) DOI: 10.1016/j.jaci.2008.10.044 Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 Trial flow diagram. Journal of Allergy and Clinical Immunology 2009 123, 167-173.e7DOI: (10.1016/j.jaci.2008.10.044) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 Rhinoconjunctivitis medication use, entire grass pollen season. Left, Percentage of subjects with medication use. Right, Total percentage of diary records (days) with medication use. ∗Statistically significant difference between treatment groups (Fisher exact test). #Statistically significant difference between treatment groups in the prevalence of days with use of the concerned relief medication (generalized linear mixed model). Journal of Allergy and Clinical Immunology 2009 123, 167-173.e7DOI: (10.1016/j.jaci.2008.10.044) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 3 Immunology results reported as change from baseline for each of the 2 treatment groups at different time points, with 95% CIs. A, Mean levels of P pratense–specific IgE antibodies. B, Mean levels of P pratense–specific IgG4 antibodies. C, IgE-blocking factor, P pratense (mean values). Journal of Allergy and Clinical Immunology 2009 123, 167-173.e7DOI: (10.1016/j.jaci.2008.10.044) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Distribution of subjects in each treatment group with regard to length of treatment evaluated by number of days from the day of first tablet intake to the day of last tablet intake. Journal of Allergy and Clinical Immunology 2009 123, 167-173.e7DOI: (10.1016/j.jaci.2008.10.044) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions